DoD Prostate Cancer, Clinical Trial Award

Organization
DOD
Type
DOD
Application Due Date
07-16-2020
Number
W81XWH-20-PCRP-CTA
Brief Description

The intent of the FY20 PCRP Clinical Trial Award is to accelerate the development of new interventions to decrease the burden of prostate cancer by supporting the rapid implementation of early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II). Therapeutic approaches proposed for testing through the Clinical Trial Award may include novel interventions or the testing of existing interventions for new indications in prostate cancer, but must represent hypothesis-based approaches for the treatment of prostate cancer that will have a major impact on one or more of the FY20 PCRP Overarching Challenges. Interventions may include drugs, devices, biologics, targeted radionuclides, surgical procedures, behavior modifications, or other types of interventions based on investigator discretion. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform prostate cancer patient care. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm.